| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.8 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |